@@%BRANCH%@@
IOS & Android
扫码下载,手机畅享 Bitop 交易新体验

更多下载方式

注册
市场
交易
现货
差价合约
竞猜
跟单交易
$
一键买币
C2C
支持
公告
帮助中心
法律中心
其他
推荐
闪兑
奖励中心
竞猜奖池
最新
下载
语言
简体中文
English
继续使用旧版本
最新资讯

[Bitop Review] Nasdaq Files Application with SEC to Include XRP, SOL, XLM, and ADA in Crypto Index

2025年06月09日发布

The Nasdaq exchange has applied to expand its Nasdaq Crypto Index (NCI), planning to include four prominent altcoins—Ripple (XRP), Solana (SOL), Stellar Lumens (XLM), and Cardano (ADA)—in its digital asset benchmark index, NCI.


The application was submitted to the U.S. Securities and Exchange Commission (SEC) on June 2. This move could broaden the investment spectrum for instruments like the Hashdex Nasdaq Crypto Index U.S. ETF (NCIQ) and is seen by the market as a step toward greater regulatory visibility for digital assets within traditional financial frameworks.


Why is Nasdaq doing this?


According to Nasdaq’s 19b-4 rule change filing, the core objective is to shift the tracking benchmark of the Hashdex Nasdaq Crypto Index U.S. ETF (NCIQ) from the current Nasdaq Crypto U.S. Settlement Price Index (NCIUS) to the broader Nasdaq Crypto Index (NCI).

The current NCI index already includes nine cryptocurrencies: Bitcoin (BTC), Ethereum (ETH), XRP, SOL, ADA, XLM, Chainlink (LINK), Litecoin (LTC), and Uniswap (UNI).


Although the NCIUS index has been updated to include six assets, the NCIQ ETF’s holdings remain heavily concentrated in Bitcoin and Ethereum (together accounting for over 87%). This allocation creates a risk of tracking error, where the ETF’s performance deviates from its benchmark index.


By including a broader range of crypto assets, Nasdaq aims to enable the NCIQ ETF to more accurately reflect the NCI index, providing investors with a truer representation of the crypto market.


Awaiting SEC Approval


The proposal’s approval hinges on SEC review. Through the 19b-4 filing, Nasdaq has requested changes to introduce new products or rules. The SEC has until November 2, 2025, to make a final decision. However, market sentiment suggests approval is likely.

 

 

Disclaimer: None of the information contained here constitutes an offer (or solicitation of an offer) to buy or sell any currency, product or financial instrument, to make any investment, or to participate in any particular trading strategy.